JP7689116B2 - Ｐｄ１およびｖｅｇｆｒ２二重結合剤 - Google Patents

Ｐｄ１およびｖｅｇｆｒ２二重結合剤 Download PDF

Info

Publication number
JP7689116B2
JP7689116B2 JP2022521074A JP2022521074A JP7689116B2 JP 7689116 B2 JP7689116 B2 JP 7689116B2 JP 2022521074 A JP2022521074 A JP 2022521074A JP 2022521074 A JP2022521074 A JP 2022521074A JP 7689116 B2 JP7689116 B2 JP 7689116B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
sequence comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553908A (ja
JP2022553908A5 (OSRAM
Inventor
ジェームズ ジョナサン フィンレー，ウィリアム
Original Assignee
オッティモ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オッティモ ファーマ リミテッド filed Critical オッティモ ファーマ リミテッド
Publication of JP2022553908A publication Critical patent/JP2022553908A/ja
Publication of JP2022553908A5 publication Critical patent/JP2022553908A5/ja
Priority to JP2025087525A priority Critical patent/JP2025134713A/ja
Application granted granted Critical
Publication of JP7689116B2 publication Critical patent/JP7689116B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022521074A 2019-10-11 2020-10-09 Ｐｄ１およびｖｅｇｆｒ２二重結合剤 Active JP7689116B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087525A JP2025134713A (ja) 2019-10-11 2025-05-26 Ｐｄ１およびｖｅｇｆｒ２二重結合剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201914747A GB201914747D0 (en) 2019-10-11 2019-10-11 PD1 and vegfr2 dual-binding agents
GB1914747.9 2019-10-11
GBGB2013180.1A GB202013180D0 (en) 2019-10-11 2020-08-24 Pd1 and vegfr2 dual-binding agents
GB2013180.1 2020-08-24
PCT/EP2020/078427 WO2021069670A1 (en) 2019-10-11 2020-10-09 Pd1 and vegfr2 dual-binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087525A Division JP2025134713A (ja) 2019-10-11 2025-05-26 Ｐｄ１およびｖｅｇｆｒ２二重結合剤

Publications (3)

Publication Number Publication Date
JP2022553908A JP2022553908A (ja) 2022-12-27
JP2022553908A5 JP2022553908A5 (OSRAM) 2023-10-17
JP7689116B2 true JP7689116B2 (ja) 2025-06-05

Family

ID=68619556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521074A Active JP7689116B2 (ja) 2019-10-11 2020-10-09 Ｐｄ１およびｖｅｇｆｒ２二重結合剤
JP2025087525A Pending JP2025134713A (ja) 2019-10-11 2025-05-26 Ｐｄ１およびｖｅｇｆｒ２二重結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087525A Pending JP2025134713A (ja) 2019-10-11 2025-05-26 Ｐｄ１およびｖｅｇｆｒ２二重結合剤

Country Status (20)

Country Link
US (2) US20240101674A1 (OSRAM)
EP (3) EP4570824A3 (OSRAM)
JP (2) JP7689116B2 (OSRAM)
KR (1) KR20220091490A (OSRAM)
CN (2) CN114981301B (OSRAM)
AU (1) AU2020365021A1 (OSRAM)
CA (2) CA3156096C (OSRAM)
DK (1) DK4041763T3 (OSRAM)
ES (1) ES3027238T3 (OSRAM)
FI (1) FI4041763T3 (OSRAM)
GB (2) GB201914747D0 (OSRAM)
HR (1) HRP20250523T1 (OSRAM)
HU (1) HUE071341T2 (OSRAM)
IL (1) IL292158A (OSRAM)
LT (1) LT4041763T (OSRAM)
PL (1) PL4041763T3 (OSRAM)
PT (1) PT4041763T (OSRAM)
RS (1) RS66837B1 (OSRAM)
SI (1) SI4041763T1 (OSRAM)
WO (1) WO2021069670A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
CN116143935A (zh) * 2021-11-22 2023-05-23 杭州翰思生物医药有限公司 重组抗体及其应用
CN119654343A (zh) * 2022-08-09 2025-03-18 上海济煜医药科技有限公司 一种靶向pd-1和vegf的抗体及其应用
CN118620082A (zh) * 2023-03-10 2024-09-10 南京维立志博生物科技有限公司 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085847A1 (zh) 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2019170885A1 (en) 2018-03-08 2019-09-12 Ultrahuman Eight Limited Pd1 binding agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
JP6312659B2 (ja) * 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
DK3356411T3 (da) 2015-10-02 2021-09-06 Hoffmann La Roche Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP2022512822A (ja) 2018-11-06 2022-02-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗ｐｄ－１抗体の使用
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085847A1 (zh) 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2019170885A1 (en) 2018-03-08 2019-09-12 Ultrahuman Eight Limited Pd1 binding agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Res.，2016年，Vol. 76, Suupl. 14，Abstract No. 572

Also Published As

Publication number Publication date
US20240101674A1 (en) 2024-03-28
JP2025134713A (ja) 2025-09-17
FI4041763T3 (fi) 2025-05-15
GB201914747D0 (en) 2019-11-27
IL292158A (en) 2022-06-01
CA3156096A1 (en) 2021-04-15
EP4570824A2 (en) 2025-06-18
CA3289307A1 (en) 2026-03-02
PT4041763T (pt) 2025-05-16
ES3027238T3 (en) 2025-06-13
CN114981301B (zh) 2026-04-14
SI4041763T1 (sl) 2025-08-29
EP4041763A1 (en) 2022-08-17
GB202013180D0 (en) 2020-10-07
CN114981301A (zh) 2022-08-30
PL4041763T3 (pl) 2025-07-07
EP4041763B1 (en) 2025-02-26
US12479920B2 (en) 2025-11-25
RS66837B1 (sr) 2025-06-30
WO2021069670A1 (en) 2021-04-15
LT4041763T (lt) 2025-06-10
AU2020365021A1 (en) 2022-05-26
DK4041763T3 (da) 2025-05-19
US20250243276A1 (en) 2025-07-31
EP4570824A3 (en) 2025-06-25
CN121758618A (zh) 2026-03-31
HRP20250523T1 (hr) 2025-07-04
KR20220091490A (ko) 2022-06-30
EP4671279A2 (en) 2025-12-31
JP2022553908A (ja) 2022-12-27
CA3156096C (en) 2026-03-17
HUE071341T2 (hu) 2025-08-28

Similar Documents

Publication Publication Date Title
IL275657B1 (en) c-kit antibodies
US12415861B2 (en) Anti C-MET antibodies
US20210101981A1 (en) Pd1 binding agents
US12479920B2 (en) PD1 and VEGFR2 dual-binding agents
US20210189003A1 (en) De-immunised anti-erbb3 antibodies
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof
KR20180010178A (ko) Jag1에 결합하는 항체 치료제
HK40075900A (en) Pd1 and vegfr2 dual-binding agents
HK40075900B (en) Pd1 and vegfr2 dual-binding agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250526

R150 Certificate of patent or registration of utility model

Ref document number: 7689116

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150